Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage TICH-2 - Tranexamic acid for IntraCerebral Haemorrhage TICH-2

niversity of Nottingham0 个研究点目标入组 2,000 人开始时间: 2015年8月21日最近更新: 2018年1月29日

适应症

试验速览

暂无简介。

•Adult (=18 years) patients with acute PICH within 8 hours of stroke onset. (Where stroke onset time is unknown, the time of when last known well will be used.)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 667
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1333

•1)Patients with intracerebral haemorrhage secondary to anticoagulation, thrombolysis or known underlying structural abnormality such as arterial venous malformation, aneurysm, tumour, venous thrombosis as cause for the intracerebral haemorrhage.. Note it is not necessary to exclude an underlying abnormality prior to enrolment, but where a secondary cause of haemorrhage is known, these patients should not be recruited.
•2)Patients for whom tranexamic acid is thought to be contraindicated.
•3)Patients with pre-morbid dependency (mRS>4).
•4)Participation in another drug trial concurrently.
•5)Pre-stroke life expectancy <3 months (eg. advanced metastatic cancer).
•6)Coma – Glasgow coma scale <5

发起方

niversity of Nottingham